SRR1476279
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.367
- KRAS_SIGNALING_DN+0.265
- APICAL_SURFACE+0.244
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.177
- ESTROGEN_RESPONSE_LATE+0.145
- APICAL_JUNCTION+0.116
- XENOBIOTIC_METABOLISM+0.116
- COAGULATION+0.097
- FATTY_ACID_METABOLISM+0.096
- ESTROGEN_RESPONSE_EARLY+0.074
Top 10 suppressed
- MYC_TARGETS_V1-0.536
- E2F_TARGETS-0.515
- G2M_CHECKPOINT-0.503
- UNFOLDED_PROTEIN_RESPONSE-0.500
- MTORC1_SIGNALING-0.467
- MYC_TARGETS_V2-0.461
- PROTEIN_SECRETION-0.398
- TNFA_SIGNALING_VIA_NFKB-0.371
- DNA_REPAIR-0.364
- NOTCH_SIGNALING-0.338
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR612899 | GTEX | — | 0.919 |
| 2 | SRR1466641 | GTEX | — | 0.915 |
| 3 | SRR614155 | GTEX | — | 0.914 |
| 4 | SRR1075898 | GTEX | — | 0.906 |
| 5 | SRR1470397 | GTEX | — | 0.895 |
| 6 | SRR1408769 | GTEX | — | 0.893 |
| 7 | SRR1379450 | GTEX | — | 0.890 |
| 8 | SRR1330675 | GTEX | — | 0.889 |
| 9 | SRR1417505 | GTEX | — | 0.886 |
| 10 | SRR1316127 | GTEX | — | 0.886 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.367 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.265 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.244 | Temsirolimus | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.177 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.145 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.116 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.116 | Inavolisib | — uncovered |
| COAGULATION | 0.097 | Binimetinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.096 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.074 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.062 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.054 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.026 | Temsirolimus | — uncovered |
| PEROXISOME | 0.015 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.011 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.009 | Inavolisib | — uncovered |